drugset / Trial / NCT05217537

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

NCT05217537

Phase 1 Completed 23 enrolled Paratek Pharmaceuticals Inc
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the pharmacokinetics of a single dose of intravenous or oral omadacycline in children and adolescents with suspected or confirmed bacterial infections.

Timeline

Start
2022-04-06
Primary completion
2025-02-27
Completion
2025-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Omadacycline Small molecule 100 mg Intravenous
Subject Omadacycline Small molecule 300 mg Intravenous